A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

May 11, 2016

Primary Completion Date

March 6, 2019

Study Completion Date

August 21, 2022

Conditions
LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Interventions
DRUG

Durvalumab

Administered as an IV infusion (250 mL) over approximately 1 hour in duration

DRUG

Lenalidomide

Administered orally

DRUG

Rituximab

Administered by intravenous infusion

DRUG

Ibrutinib

Administered orally

DRUG

Bendamustine

Administered as a 30-minute intravenous infusion

Trial Locations (66)

10065

Weill Cornell Medical College, New York

13273

Institut Paoli Calmettes, Marseille

14642

Local Institution - 005, Rochester

University of Rochester, Rochester

19107

Jefferson Medical Oncology Associates, Philadelphia

20089

IRCCS Humanitas Clinical Institute, Rozzano (milano)

20144

IEO- Istituto Europeo di Oncologia, Milan

20162

A.O. Ospedale Ca Granda - Niguarda, Milan

21079

Centre Hospitalier, Dijon

25123

Local Institution - 306, Brescia

Spedali Civili Di Brescia, Brescia

27100

I.R.C.C.S. Policlinico San Matteo, Pavia

30322

Emory University, Atlanta

32610

Shands Cancer Center University of Florida, Gainesville

33604

Hopital Haut Leveque, Pessac

33612

Moffitt Cancer Center, Tampa

34295

CHU Montpellier, Montpellier

Local Institution - 102, Montpellier

35033

CHRU Rennes, Rennes

37099

UKG Universitatsklinikum Gottingen, Göttingen

40138

University of Bologna, Bologna

43210

The Ohio State University, Columbus

44093

Centre Hospitalier Universitaire de Nantes, Nantes

Local Institution - 105, Nantes

45122

Universitatsklinikum Essen, Essen

50924

Universitatsklinik Koln, Köln

55905

Mayo Clinic, Rochester

60611

Northwestern University Feinberg School of Medicine, Chicago

63110

Washington University School of Medicine, St Louis

66421

Universitatsklinikum des Saarlandes, Homburg-Saar

69495

Centre Hospitalier Lyon-Sud, Pierre-Bénite

Local Institution - 103, Pierre-Bénite

73104

University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City

76038

Centre Henri Becquerel, Rouen

77030

Houston Methodist Cancer Center, Houston

MD Anderson Cancer Center, Houston

80045

University of Colorado Cancer Center, Aurora

80131

Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale, Napoli, Campania

Local Institution - 304, Napoli, Campania

81377

Medizinische Klinik III Klinikum der Universität München-Großhadern, München

85234

Banner MD Anderson Cancer Center, Gilbert

85258

Pinnacle Oncology Hematology, Scottsdale

93009

Centre Hospitalier Universitaire d'Avicennes, Bobigny

94010

Hopital Henri Mondor, Créteil

07601

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack

77030-4009

MD Anderson Cancer Center, Houston

104-0045

Local Institution - 602, Chuo-ku

National Cancer Center Hospital, Chūōku

259-1193

Tokai University Hospital, Isehara City, Kanagawa

464-8681

Aichi Cancer Center, Nagoya

1081 HV

VU Academic Medical Center, Amsterdam, Amsterdam

9713 GZ

UMC Groningen, Groningen

2333 ZA

Leids Universitair Medisch Centrum, Leiden

3015 CN

Erasmus Medical Center, Rotterdam

Local Institution - 501, Rotterdam

PL6 8DH

Local Institution - 402, Plymouth

Derriford Hospital, Plymouth

NG5 1PB

Local Institution - 407, Nottingham

LS9 7TF

St James University Hospital, Leeds

WC1E 6BT

UCL Cancer Institute, London

M20 4BX

Christie Hospital NHS Trust, Manchester

Local Institution - 404, Manchester

Ng5 1PB

Nottingham University Hospitals NHS Trust, Nottingham

0X3 7LE

Local Institution - 406, Oxford

Oxford University Hospitals NHS Trust- Churchill Hospital-Oxford Centre for Respiratory Medicine, Oxford

SO16 6YD

Southampton University Hospitals NHS Trust, Southampton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY